title: In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells.
abstract: Diagnostic material from patients with leishmaniasis is generally available as promastigotes, and proper testing for susceptibility to first-line drugs by the intracellular amastigote assay is frequently hampered by the poor infectivity of the promastigotes for the macrophage host cell. Several conditions for optimization of the in vitro metacyclogenesis and cell infectivity of Leishmania donovani, L. guyanensis, and L. braziliensis field strains obtained from patients receiving standard antimony medication were investigated. Triggering log-phase promastigotes to become amastigote-like by increasing the temperature or acidifying the culture medium was not successful. Adequate metacyclogenesis and the highest levels of macrophage infection were obtained after 5-day-old late-log-phase promastigote cultures were preconditioned at 25 degrees C to pH 5.4 for 24 h in Schneider's medium prior to infection. The susceptibility assay with primary peritoneal mouse macrophages included pentavalent antimony (Sb(V); sodium stibogluconate), trivalent antimony (Sb(III); potassium antimonyl tartrate), miltefosine, and the experimental drug PX-6518. All strains were sensitive to miltefosine (50% inhibitory concentration [IC(50)] < 10 microM) and PX-6518 (IC(50) < 2 microg/ml) but showed distinct susceptibility to Sb(V) and/or Sb(III), depending on whether they were derived from cured, relapse, or nonresponder patients. Within the available set of Leishmania species and strains, simultaneous Sb(V)-Sb(III) resistance was clearly associated with treatment failure; however, a larger set of isolates is still needed to judge the predictive value of Sb(V)-Sb(III) susceptibility profiling on treatment outcome. In conclusion, the proposed conditioning protocol further contributes toward a more standardized laboratory model for evaluation of the drug sensitivities of field isolates.
authors.affiliation: Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp, Belgium.
authors.forename: Raquel Inocêncio
authors.initials: RI
authors.lastname: da Luz
authors.forename: Marieke
authors.initials: M
authors.lastname: Vermeersch
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Dujardin
authors.forename: Paul
authors.initials: P
authors.lastname: Cos
authors.forename: Louis
authors.initials: L
authors.lastname: Maes
mesh_terms: D000818:Animals; D000967:Antimony Sodium Gluconate / Q000494:pharmacology; D000981:Antiprotozoal Agents / Q000494:pharmacology; D002478:Cells, Cultured; D005434:Flow Cytometry; D007891:Leishmania / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity*; D007896:Leishmaniasis / Q000469:parasitology*; D017737:Macrophages, Peritoneal / Q000469:parasitology*; D051379:Mice; D008853:Microscopy; D021261:Parasitic Sensitivity Tests; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000627:therapeutic use; D012503:Saponins / Q000494:pharmacology; D013696:Temperature; D014315:Triterpenes / Q000494:pharmacology
chemical_list: D000981:Antiprotozoal Agents; C481665:PX-6518; D012503:Saponins; D014315:Triterpenes; D010767:Phosphorylcholine; C039128:miltefosine; D000967:Antimony Sodium Gluconate